Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-EDGE treatment-experienced trial [P0886] | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-EDGE treatment-experienced trial [P0886]

Kwo PY, Gane EJ, Peng C-Y, et al. Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-EDGE treatment-experienced trial [P0886]. J Hepatol. 2015;62(Suppl 2):S674-S675.

Publication Type:

Journal Article

Authors:

P Y Kwo; E J Gane; Peng, C-Y; et, al

Source:

J Hepatol, Volume 62, Issue Suppl 2, p.S674-S675 (2015)

Cited On:

Export Citation:

RIS Format

Top